Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2018
(WorldNews Denmark)

Company Announcement Net sales of DARZALEX in the first quarter of 2018 totaled USD 432 million Genmab will receive royalties on worldwide sales from Janssen Biotech, Inc. Copenhagen, Denmark; April 17, 2018 - Genmab A/S (Nasdaq Copenhagen: GEN) announced today that worldwide net sales of DARZALEX (daratumumab) as reported by Johnson & Johnson were USD 432 million in the first quarter of 2018. Net sales were USD 264 million in the U.S. and USD 168 million in the rest of the world. Genmab will receive royalties on the worldwide net sales of DARZALEX under the exclusive worldwide license to Janssen Biotech, Inc. to develop, manufacture and commercialize DARZALEX. About DARZALEX®(daratumumab)...